ALOPECIA AREATA

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo by IV. The goal is to see if the drug can regrow hair and is safe, with the study lastin…

This study tests a new drug called LAD603 for adults with severe to very severe alopecia areata, a condition causing major hair loss on the scalp. About 136 people will receive either the drug or a placebo to see if it helps hair regrow and is safe. The main goal is to measure ch…

This study tests whether the drug upadacitinib can safely regrow hair in people with severe alopecia areata, a condition where the immune system attacks hair follicles. About 1,500 adults and teens will take a daily pill or placebo for up to 160 weeks. The main goal is to see if …

This study tests a new medicine called FB102 for people with severe to very severe alopecia areata, a condition causing major hair loss. About 32 adults will receive either FB102 or a placebo to see if it is safe and helps hair grow back. The main goal is to check for side effect…

This study tests an oral drug called upadacitinib for people with severe alopecia areata, an autoimmune condition that causes patchy or total scalp hair loss. About 123 adults and teens in Japan with at least 25% hair loss will take either the drug or a placebo daily for up to 2 …

This study tests whether transplanting healthy gut bacteria (microbiota transplant therapy) can help people with moderate to severe alopecia areata regrow hair. About 40 adults aged 18-75 with patchy or total hair loss will receive the treatment. Researchers will track changes in…

This study tests whether microneedling combined with either lactic acid, vitamin D3, or a steroid (triamcinolone acetonide) can help regrow hair in people with patchy alopecia areata. About 88 participants aged 16 and older with small bald patches will receive one of the three co…

This study tests a new drug called NXC736 for people with moderate to severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. About 73 adults aged 19 to 65 will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug s…

This study tests whether deuruxolitinib, an oral medication, can safely help teenagers aged 12 to 17 with severe alopecia areata regrow scalp hair. Participants must have at least 50% hair loss and will be randomly assigned to receive the drug or a placebo for 24 weeks, followed …

This study tests if dupilumab can help children aged 6 to 17 with moderate to severe alopecia areata, a condition causing patchy hair loss. About 76 kids will receive either the drug or a placebo for 48 weeks, followed by an open-label phase. The goal is to see if the treatment c…

This study tests whether the drug ruxolitinib can help hair regrow in people with APECED, a rare immune disorder, who also have severe alopecia areata (hair loss). About 70 participants aged 12 to 75 will take ruxolitinib pills twice daily for 8 months. Researchers will measure h…

This early-stage study tests whether injecting cyclosporine directly into bald patches can safely regrow hair in people with alopecia areata, an autoimmune condition causing patchy hair loss. About 12 adults with mild to moderate hair loss will receive either the drug or a placeb…

This study follows 850 people with alopecia areata who are taking the approved drug ritlecitinib. Researchers will measure hair regrowth and quality of life over time in real-world clinics. The goal is to see how well the treatment works outside of controlled trials.

This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or patchy hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin and scalp problems. The goal is to manage symptoms, not cure the…

This program offers early access to ritlecitinib, an experimental pill, for people with severe alopecia areata who have lost at least half of their scalp hair and have not improved with standard treatments. The goal is to provide a potential treatment option before the drug is fu…

This study is testing a new laser (PALLAS) to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 adults will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition and i…

This study looks at how alopecia areata, vitiligo, and hidradenitis suppurativa affect the daily lives of teens and adults. Researchers will survey nearly 2,800 people worldwide to measure symptoms, hair loss, skin changes, and quality of life. The goal is to better understand th…

This study will follow about 5,000 adults with alopecia areata (a condition causing patchy hair loss) to learn more about how the disease develops, changes, and is managed over time. Participants will be under the care of a dermatologist and will be taking or starting a medicatio…

This study is a registry that will follow 1,500 teenagers (ages 12-17) with severe alopecia areata, an autoimmune condition causing hair loss. Researchers will collect information from routine doctor visits to learn more about the disease, how it is treated, and what happens over…